1428336-32-6

Basic information

• Product Name: C₂₃H₁₉BrN₄O₃
• Synonyms: C₂₃H₁₉BrN₄O₃
• CAS NO: 1428336-32-6
• Molecular Weight: 479.333
• Mol File: 1428336-32-6.mol

Chemical Properties

• CAS DataBase Reference: C₂₃H₁₉BrN₄O₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₃H₁₉BrN₄O₃(1428336-32-6)
• EPA Substance Registry System: C₂₃H₁₉BrN₄O₃(1428336-32-6)

Safety Data

• Hazardous Substances Data: 1428336-32-6(Hazardous Substances Data)

Upstream product

• 21190-87-4 6-bromo-pyridine-2-carboxylic acid 
• 1428336-31-5 2-morpholino-4-phenylbenzo[d]oxazol-6-amine 
• 915156-09-1 2-amino-3-bromo-5-nitro-phenol 
• 1428335-92-5 C₇H₃BrN₂O₃S 
• 1428335-93-6 4-bromo-2-morpholino-6-nitrobenzo[d]oxazole 
• 1428335-91-4 4-bromo-2-morpholinobenzo[d]oxazol-6-amine 

Downstream Products

• 1428335-53-8 C₂₈H₂₄N₆O₃ 
• 1428335-52-7 C₃₀H₂₄N₆O₃ 

Relevant articles and documents

BICYCLIC HETEROCYCLES AS IRAK4 INHIBITORS

The present invention provides bicyclic heterocycle kinase enzyme inhibitor compounds of formula (I), which may be therapeutically useful as kinase inhibitor, more particularly IRAK4 inhibitors. ( I ) in which A, R, R1,R2, m, n and p have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly IRAK4 enzyme.The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.